

Resource Summary Report

Generated by [dkNET](#) on Jul 29, 2026

FITC anti-human CD3

RRID:AB_314059

Type: Antibody

Proper Citation

BioLegend Cat# 300405, RRID:AB_314059

Antibody Information

URL: http://antibodyregistry.org/AB_314059

Proper Citation: BioLegend Cat# 300405, RRID:AB_314059

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: FITC anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone UCHT1

Antibody ID: AB_314059

Vendor: BioLegend

Catalog Number: 300405

Alternative Catalog Numbers: 300406, 300452, 300440

Record Creation Time: 20250820T013638+0000

Record Last Update: 20250820T112308+0000

Ratings and Alerts

No rating or validation information has been found for FITC anti-human CD3.

No alerts have been found for FITC anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Kouro T, et al. (2025) Improvement in the function of self-activating chimeric antigen receptor by replacing the linker sequence. *Frontiers in immunology*, 16, 1502607.

Xu Y, et al. (2025) Microbiota metabolite taurodeoxycholic acid maintains intestinal tissue residency of innate lymphoid cells via engagement with P2Y10 receptor. *Science advances*, 11(34), eadt9645.

Wientjens C, et al. (2025) Tolerance to ferroptosis facilitates lipid metabolism and pathogenic type 2 immunity in allergic airway inflammation. *Immunity*.

Zhang D, et al. (2025) FLT3L-based drug conjugate effectively targets chemoresistant leukemia stem cells in acute myeloid leukemia. *Cell reports. Medicine*, 102365.

Amaya L, et al. (2024) Pathways for macrophage uptake of cell-free circular RNAs. *Molecular cell*, 84(11), 2104.

Mathews JA, et al. (2024) Single cell profiling of hematopoietic stem cell transplant recipients reveals TGF- β 1 and IL-2 confer immunoregulatory functions to NK cells. *iScience*, 27(12), 111416.

Pedde AM, et al. (2024) Tissue-colonizing disseminated tumor cells secrete prostaglandin E2 to promote NK cell dysfunction and evade anti-metastatic immunity. *Cell reports*, 43(11), 114855.

Lin F, et al. (2024) Multimodal targeting chimeras enable integrated immunotherapy leveraging tumor-immune microenvironment. *Cell*, 187(26), 7470.

Bayerl F, et al. (2023) Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses. *Immunity*, 56(6), 1341.

Hasegawa T, et al. (2023) Cytotoxic CD4⁺ T cells eliminate senescent cells by targeting cytomegalovirus antigen. *Cell*, 186(7), 1417.

Song Z, et al. (2023) Targeting of Annexin A1 in Tumor-associated Macrophages as a therapeutic strategy for hepatocellular carcinoma. *Biochemical pharmacology*, 213, 115612.

Bennstein SB, et al. (2020) Umbilical cord blood-derived ILC1-like cells constitute a novel precursor for mature KIR+NKG2A- NK cells. *eLife*, 9.

Huang N, et al. (2020) Natural display of nuclear-encoded RNA on the cell surface and its impact on cell interaction. *Genome biology*, 21(1), 225.